Prostatectomy Denied by Insurance? How to Appeal When Prostate Cancer Treatment Is Rejected

Radical prostatectomy — surgical removal of the prostate — is one of the primary curative treatments for localized prostate cancer. When an insurer denies coverage for this procedure, it feels not just unjust but frightening. Denials typically arise from disagreements about cancer risk stratification, the appropriateness of active surveillance, or the surgical approach chosen. Here's how to understand and fight the denial.

Why Prostatectomy Claims Get Denied

Active surveillance argument for low-risk disease. This is the most common denial scenario. The National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) recognize active surveillance (AS) as an appropriate management option for low-risk prostate cancer (PSA <10, Gleason 6 / Grade Group 1, clinical stage T1c–T2a). Insurers may deny immediate prostatectomy for low-risk disease, arguing that active surveillance should be pursued first.

PSA level disputes. PSA (prostate-specific antigen) levels are one factor in risk stratification, but PSA alone does not determine the appropriateness of treatment. Insurers sometimes focus narrowly on a PSA below a threshold and deny surgery, even when biopsy results and other factors support treatment.

Gleason score or Grade Group boundary cases. Prostate cancer grading has evolved: the Gleason system has been reformulated into Grade Groups 1–5. Grade Group 1 (Gleason 6) is generally low-risk; Grade Group 2 (Gleason 3+4=7) is intermediate-risk, where treatment is more clearly appropriate. If your pathology report straddles these boundaries — for example, a small amount of Gleason 4 pattern — the insurer may dispute the risk classification.

Number of positive biopsy cores. Risk stratification also considers the percentage and number of biopsy cores showing cancer. An insurer may argue that limited core involvement supports observation rather than surgery.

Robotic vs. open prostatectomy disputes. Robot-assisted laparoscopic radical prostatectomy (RALP) is now the most common approach in the US. Some older or more restrictive plans may classify robotic surgery as experimental or may dispute the incremental cost over open prostatectomy. Most courts and regulators have ruled that robotic prostatectomy is standard of care, but disputes still occur.

Radiation as equivalent alternative. For localized prostate cancer, radiation therapy (external beam radiation or brachytherapy) is considered equivalent to surgery for most risk groups. An insurer may approve radiation but deny surgery, or vice versa, based on plan-specific coverage policies. This is not appropriate — the patient and physician should have the right to choose between equivalent treatments.

BPH vs. cancer denial. For prostatectomy performed for benign prostatic hyperplasia (BPH) — such as simple prostatectomy or HoLEP — insurers require documentation that the enlarged prostate is causing significant obstructive symptoms, failed medical management (alpha-blockers, 5-alpha reductase inhibitors), and has an appropriate prostate volume and flow rate on urodynamic testing.

Risk Stratification and Why It Matters

NCCN prostate cancer risk stratification is the standard framework:

• Very low risk: Consider active surveillance in most cases
• Low risk: Active surveillance preferred for most; treatment appropriate for patients with life expectancy >10 years who prefer to avoid surveillance
• Intermediate risk (favorable): Active surveillance an option for some; treatment recommended for most
• Intermediate risk (unfavorable) and High risk: Treatment (surgery or radiation) recommended

If your cancer is classified as intermediate-risk (unfavorable) or high-risk, surgical treatment is clearly appropriate under guidelines and a denial on "active surveillance" grounds is not defensible.

Building Your Appeal

Provide the complete pathology report. This includes: PSA at diagnosis, clinical staging information (DRE findings, MRI results if performed), biopsy pathology with all core results (number cores taken, number positive, percent involvement, highest Gleason pattern in each core, overall Gleason score and Grade Group), and any staging imaging (bone scan, pelvic MRI, PSMA PET if performed).

Include an mpMRI report if available. Multiparametric MRI (mpMRI) of the prostate with a PI-RADS score provides important staging information, particularly for identifying extra-prostatic extension. A high PI-RADS score or visible index lesion strengthens the case for treatment over surveillance.

Get a letter from your urologist or urologic oncologist. The letter should explicitly state NCCN risk category, explain why active surveillance is not appropriate or preferred for your specific situation (patient age, life expectancy, tumor characteristics, patient preference), cite NCCN and AUA guidelines, and address the treatment approach chosen.

Address the radiation equivalence argument. If the insurer approved radiation but denied surgery, your physician should document why you chose surgery — including shared decision-making, side effect profile considerations, and patient preference, which is a recognized factor in prostate cancer treatment decisions.

After an Internal Denial

Request external independent review by a urologist or urologic oncologist. Cancer treatment denials are among the most successful on external review when clinical documentation supports the treatment decision.

Fight Back With ClaimBack

Your cancer treatment shouldn't be decided by an insurance adjuster. ClaimBack helps you build a compelling, guideline-backed appeal to get coverage for the care your physician recommends.

Start your appeal at ClaimBack

Related Reading

• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?
• How to Write an Insurance Appeal Letter